Daily supplement may help ease MS fatigue, small trial suggests

More studies needed to investigate long-term effects of supplementation

Written by Andrea Lobo, PhD |

A person pours pills from a bottle into their hand.

A daily supplement combining probiotics and prebiotics may help manage fatigue in people with multiple sclerosis, according to a small clinical trial. (Photo from iStock)

  • A small clinical trial found that a daily supplement significantly eased fatigue severity in MS patients.
  • Familact is a synbiotic daily supplement, meaning it combines probiotics and prebiotics.
  • Larger, multicenter studies are necessary to validate these preliminary findings and understand long-term supplement efficacy.

A daily supplement combining probiotics and prebiotics may help manage fatigue in people with multiple sclerosis (MS), according to a small clinical trial.

Probiotics are live microorganisms thought to help with gut health, while prebiotics are substances that support beneficial gut microbes.

Data showed that participants taking Familact, a supplement containing nine bacterial strains and a prebiotic, daily for 30 days had significantly less severe fatigue than those receiving a placebo.

“The findings of this study highlighted the positive impact of probiotics and prebiotics with nine bacterial strains in alleviating fatigue in these patients,” researchers wrote. “While further research is required, these results open the door to exploring probiotic‑based interventions for managing neurological disorders.”

The study, “The Role of Synbiotics in Alleviating Fatigue Among Multiple Sclerosis Patients: A Randomized Controlled Trial,” was published in the International Journal of Preventive Medicine.

Recommended Reading
Assorted pills and capsules surrounding a magnifying glass on a light blue background.

Experimental MS therapy outperforms approved treatment in two trials

Familact contains both probiotics and prebiotics

MS occurs when the immune system attacks healthy tissues in the brain and spinal cord, disrupting the transmission of nerve signals. This leads to a wide range of symptoms, including physical, sensory, and cognitive problems. Fatigue is particularly common and can substantially affect patients’ quality of life and their ability to carry out everyday activities.

Increasing evidence suggests that the gut microbiome, the community of microorganisms that live in the digestive tract, may contribute to the inflammation associated with MS. By influencing the balance of bacteria in the gut, probiotics may help regulate immune activity and reduce inflammation, two factors thought to contribute to MS-related fatigue.

Indeed, some studies have shown that probiotic supplements may help ease fatigue in people with MS. In this study, a team of researchers in Iran conducted a clinical trial to evaluate whether a supplement combining probiotics and prebiotics could reduce fatigue and improve overall well-being in people with MS.

Called Familact, the evaluated supplement is a synbiotic, meaning it contains both probiotics and prebiotics. Familact contains nine bacterial strains, including species of Lactobacillus and Bifidobacterium, and fructooligosaccharides, a prebiotic found in plants.

Recommended Reading
Three blood sample tubes with red liquid and colored caps resting on printed medical charts.

B-cell therapies linked to fewer relapses in early MS, study finds

No serious adverse reactions reported during the study

The study, conducted at clinics affiliated with Arak University of Medical Sciences in Iran, involved 54 adults with relapsing-remitting MS who had not experienced relapses, or periods of worsening symptoms, in the previous three months.

Most were women and their mean age was 40.52 years. Participants were randomly assigned to receive either Familact (500 mg) or a placebo daily for 30 days, together with their usual MS medications.

Researchers assessed fatigue before and after treatment using the Fatigue Severity Scale (FSS), a nine-item questionnaire that measures the severity and impact of fatigue.

At the start of the study, mean fatigue scores were similar in the Familact and placebo groups. While both groups showed a significant increase in FSS scores, reflecting increased fatigue, over 30 days, this score increase was significantly smaller in the Familact group (by 2.23 vs. 5.44).

Statistical analyses adjusted for initial FSS scores showed that patients receiving the supplement had significantly lower mean FSS scores than those on the placebo after 30 days (39.73 vs. 44.36).

These findings align with previous studies suggesting that probiotics may positively impact neurological conditions by influencing [blood] levels of factors associated with [body-wide] inflammation.

No serious adverse reactions were reported during the study, and no participants experienced an MS relapse during or after the intervention.

“These findings align with previous studies suggesting that probiotics may positively impact neurological conditions by influencing [blood] levels of factors associated with [body-wide] inflammation,” the researchers wrote.

While the supplement’s potential benefits may be related to the effects of gut microbes on immune function and inflammation, changes in gut bacteria or inflammatory markers were not assessed in this study. The team emphasized, therefore, that the mechanisms behind the observed differences remain unclear.

The relatively small number of participants from a single country and short duration of supplementation were pointed out by the researchers as study limitations. The study also could not establish whether the effects would persist over time or apply to people with other forms of MS.

In addition, possible demographic and clinical differences between the two groups at the study’s start may have influenced the outcomes, and “caution should be exercised when interpreting the findings,” the team wrote.

“Further research involving larger, multicenter studies is necessary to validate these results and investigate the long‑term effects of probiotic supplementation,” the researchers concluded.

Leave a comment

Fill in the required fields to post. Your email address will not be published.

Comments are moderated. Once approved, your comment and username will be publicly visible. Please avoid sharing personal health information or other sensitive details.